PortViewPortView
Accuray logo

Accuray (ARAY) Stock Analysis

NASDAQHealthcareMedical - Devices

$0.26+0.27%
1-year price historyRange $0.23 – $1.85
52-week range$0.26
$0.22$2.10

What Accuray does

Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.

Key metrics

Market cap
$30.37M
P/E (TTM)
-0.64
EPS (TTM)
$-0.40
Beta
1.39
Dividend yield
0.00%
Revenue / share
$3.28
50-day avg
$0.27
200-day avg
$0.52
52-week high
$2.10
52-week low
$0.22
CEO
Stephen R. LaNeve

ETFs linked to ARAY

Broad-market and Healthcare sector ETFs an investor holding Accuray is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ARAY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ARAY in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Accuray?
Accuray trades under the ticker ARAY on NASDAQ.
Which exchange is ARAY listed on?
ARAY is listed on NASDAQ.
What sector does Accuray operate in?
Accuray is classified in the Healthcare sector (Medical - Devices industry).
How can PortView help analyze ARAY in a portfolio?
PortView shows ARAY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.